Drug Profile


Alternative Names: ALV-003; IMGX-003

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer ImmunogenX
  • Class Cysteine endopeptidases; Recombinant proteins
  • Mechanism of Action Cysteine endopeptidase stimulants; Prolyl endopeptidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coeliac disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-0 development in Coeliac disease in Australia (PO)
  • 06 May 2017 Efficacy data from a phase IIb trial in Coeliac disease released by ImmunogenX
  • 15 Mar 2016 ImmunogenX acquires latiglutenase from Alvine Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top